These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 26634680)

  • 1. Clinical implications of the global multidrug-resistant tuberculosis epidemic.
    Kumar K; Abubakar I
    Clin Med (Lond); 2015 Dec; 15 Suppl 6():s37-42. PubMed ID: 26634680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical implications of the global multidrug-resistant tuberculosis epidemic.
    Kumar K; Abubakar I
    Clin Med (Lond); 2016 Dec; 16(6):565-570. PubMed ID: 27927822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multidrug resistant tuberculosis: trends and control.
    Prasad R; Gupta N; Singh M
    Indian J Chest Dis Allied Sci; 2014; 56(4):237-46. PubMed ID: 25962197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical management of adults and children with multidrug-resistant and extensively drug-resistant tuberculosis.
    Dheda K; Chang KC; Guglielmetti L; Furin J; Schaaf HS; Chesov D; Esmail A; Lange C
    Clin Microbiol Infect; 2017 Mar; 23(3):131-140. PubMed ID: 27756712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of Multidrug-Resistant Tuberculosis.
    Daley CL; Caminero JA
    Semin Respir Crit Care Med; 2018 Jun; 39(3):310-324. PubMed ID: 30071546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The risk of global epidemic replacement with drug-resistant Mycobacterium tuberculosis strains.
    McBryde ES; Meehan MT; Doan TN; Ragonnet R; Marais BJ; Guernier V; Trauer JM
    Int J Infect Dis; 2017 Mar; 56():14-20. PubMed ID: 28163165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High fluoroquinolone resistance proportions among multidrug-resistant tuberculosis driven by dominant L2 Mycobacterium tuberculosis clones in the Mumbai Metropolitan Region.
    Dreyer V; Mandal A; Dev P; Merker M; Barilar I; Utpatel C; Nilgiriwala K; Rodrigues C; Crook DW; ; Rasigade JP; Wirth T; Mistry N; Niemann S
    Genome Med; 2022 Aug; 14(1):95. PubMed ID: 35989319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MDR Tuberculosis Treatment.
    Espinosa-Pereiro J; Sánchez-Montalvá A; Aznar ML; Espiau M
    Medicina (Kaunas); 2022 Jan; 58(2):. PubMed ID: 35208510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A close-up on the epidemiology and transmission of multidrug-resistant tuberculosis in Poland.
    Jagielski T; Brzostek A; van Belkum A; Dziadek J; Augustynowicz-Kopeć E; Zwolska Z
    Eur J Clin Microbiol Infect Dis; 2015 Jan; 34(1):41-53. PubMed ID: 25037868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapy of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis.
    Seaworth BJ; Griffith DE
    Microbiol Spectr; 2017 Mar; 5(2):. PubMed ID: 28361737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of multidrug resistant tuberculosis.
    Daley CL; Caminero JA
    Semin Respir Crit Care Med; 2013 Feb; 34(1):44-59. PubMed ID: 23460005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An update on multidrug-resistant tuberculosis .
    Park M; Satta G; Kon OM
    Clin Med (Lond); 2019 Mar; 19(2):135-139. PubMed ID: 30872297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Potential Impact of Up-Front Drug Sensitivity Testing on India's Epidemic of Multi-Drug Resistant Tuberculosis.
    Sachdeva KS; Raizada N; Gupta RS; Nair SA; Denkinger C; Paramasivan CN; Kulsange S; Thakur R; Dewan P; Boehme C; Arinaminpathy N
    PLoS One; 2015; 10(7):e0131438. PubMed ID: 26132584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors of multidrug-resistant tuberculosis: A global systematic review and meta-analysis.
    Pradipta IS; Forsman LD; Bruchfeld J; Hak E; Alffenaar JW
    J Infect; 2018 Dec; 77(6):469-478. PubMed ID: 30339803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Editorial: Updates from the World Health Organization (WHO) on Global Treatment Recommendations for Drug-Susceptible and Multidrug-Resistant Tuberculosis.
    Parums DV
    Med Sci Monit; 2021 Aug; 27():e934292. PubMed ID: 34366429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the socio-demographic and clinical features of pulmonary TB patients infected with sub-lineages within the W-Beijing and non-Beijing Mycobacterium tuberculosis.
    Hu Y; Mathema B; Zhao Q; Zheng X; Li D; Jiang W; Wang W; Xu B
    Tuberculosis (Edinb); 2016 Mar; 97():18-25. PubMed ID: 26980491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidemiology of Pediatric Multidrug-Resistant Tuberculosis in the United States, 1993-2014.
    Smith SE; Pratt R; Trieu L; Barry PM; Thai DT; Ahuja SD; Shah S
    Clin Infect Dis; 2017 Oct; 65(9):1437-1443. PubMed ID: 28633501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extensive global movement of multidrug-resistant
    Cohen KA; Manson AL; Abeel T; Desjardins CA; Chapman SB; Hoffner S; Birren BW; Earl AM
    Thorax; 2019 Sep; 74(9):882-889. PubMed ID: 31048508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Global burden of latent multidrug-resistant tuberculosis: trends and estimates based on mathematical modelling.
    Knight GM; McQuaid CF; Dodd PJ; Houben RMGJ
    Lancet Infect Dis; 2019 Aug; 19(8):903-912. PubMed ID: 31281059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fighting the tuberculosis epidemic in the Western Pacific region: current situation and challenges ahead.
    van Maaren PJ
    Kekkaku; 2010 Jan; 85(1):9-16. PubMed ID: 20143671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.